Daily doses of baclofen may help reduce the risk of agitation among individuals with unhealthy alcohol use admitted to the intensive care unit (ICU), according to results of the BACLOREA* trial presented at eCCR 2021.
De-adoption of the practice of swabbing the mouth with chlorhexidine for the prevention of ventilator-associated pneumonia (VAP) in the intensive care unit (ICU) and implementing a standard oral care bundle does not necessarily reduce mortality, infection-related ventilator-associated complications (IVACs), or procedural pain, according to the results of the CHORAL study.
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.
The systemic use of corticosteroids lowers 28-day all-cause mortality among patients with the novel coronavirus disease (COVID-19), as opposed to usual care or placebo, according to the REACT* meta-analysis presented at the recently concluded eCritical Care Reviews Meeting 2021 (eCCR21).
The propensity of the novel coronavirus disease (COVID-19) to develop into a severe and life-threatening disease appears to be influenced by genetics, according to the GenOMICC* study, whose results were recently presented at the eCritical Care Reviews Meeting 2021 (eCCR21).
In patients with acute hypoxemic respiratory failure admitted to the intensive care unit (ICU), a lower oxygenation target does not lead to a lower mortality rate, according to results of the HOT-ICU* trial presented at eCCR 2021.
Among critically ill adults receiving mechanical ventilation in the intensive care unit (ICU), a protocol of no sedation is comparable to light sedation with daily interruption in terms of mortality, as shown in the NONSEDA trial.
An accelerated renal-replacement strategy does not appear to reduce the risk of mortality at 90 days among critically ill patients with acute kidney injury (AKI) compared to a standard strategy, according to the results of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.
Adding Viscoelastic Haemostatic Assay (VHA) to empiric standard major haemorrhage protocol (MHP) in management of trauma did not improve overall outcomes compared with conventional coagulation test (CCT)-guided interventions, according to the ITACTIC* study presented at eCCR 2021.
Invasive ventilation using a lower positive end-expiratory pressure (PEEP) strategy was noninferior to higher PEEP in ICU* patients without acute respiratory distress syndrome (ARDS), according to the RELAx** study presented at eCCR 2021.